Compounded semaglutide
Sold by LaSara Medical Group · every compounded semaglutide record
The register has not established whether this program ships a vial, a pen, or another form. That is a gap in our record, not a statement about the company.
What you actually pay
Per month
$299
| Medication · 1 month | $299 |
|---|
Added from the figures recorded below.
Price
| Term | Per month | Charged today |
|---|---|---|
| 1 month “1 month $299” | Per month$299 | Charged today$299 |
| 3 months “3 months ($283 per month) $849” | Per month$283 | Charged today$849 |
| 6 months “6 months ($249 per month) $1,495” | Per month$249 | Charged today$1,495 |
| 12 months “12 months ($233 per month) $2,795” | Per month$233 | Charged today$2,795 |
We earn nothing from this link. LaSara Medical Group has no commercial arrangement with Treatment Registry, and its record here is kept to the same standard as every other.
History
One reading so far. A price history appears here after the next verification pass.
- September 2, 2026 — Entry added to the register
Sourcing and terms
| Cancellation | “Cancel or pause anytime — no questions, no fees” |
|---|
Not yet checked: pharmacy, states, prescriber, membership and consult fee.
Recorded from lasara.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.
Notes
- 1. September 2, 2026 — Homepage claims nationwide reach with a footnoted asterisk ('across the country.*') whose footnote text did not appear anywhere in the fetched output, so this is recorded as not-found rather than all-50 — the exact scope/exclusions are unknown. Tirzepatide page explicitly says 'Every vial meets federal safety and purity standards,' confirming vial form for tirzepatide; the semaglutide product page never uses the word vial, pen, or syringe, so its form is recorded as not-disclosed.
Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.